| Patient | Frédéric Chopin |
|---|---|
| Date of birth | 1998-03-01 |
| Identifiers | MRN HR-NI020-SYN; SSN (made up) 000-20-8845 |
| Document date | 2026-03-20 |
| Author | Matthias Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Results visit: tuberculosis confirmed; infectious diseases consultation and start of treatment. [S]
Mr. Chopin returns three days after his first visit, masked and seen in an airborne infection isolation room, for his results; Dr. Kowalczyk-Grant of infectious diseases sees him the same morning. He has stayed at home with no students or visitors, and his lessons have moved online. His cough and night sweats are unchanged, and he has coughed up streaks of blood once since the first visit. His three sputum smears show acid-fast bacilli (2+, 2+, and 1+), and the nucleic acid amplification test on the first sample detected Mycobacterium tuberculosis complex with no rifampin resistance; molecular tests for isoniazid and fluoroquinolone resistance and the cultures are pending. The interferon-gamma release assay is positive, HIV is negative, hepatitis B surface antigen and core antibody are negative with surface antibody positive from vaccination, and hepatitis C antibody is negative. He was relieved to have a name for the illness and asked how long treatment lasts and when he can teach again. After the four-month and six-month regimens were explained, he chose the four-month regimen and took his first observed dose with a meal in the clinic. [S]
| Element | Detail |
|---|---|
| Results | Smears 2+, 2+, 1+; amplification test positive without rifampin resistance; IGRA positive; HIV negative; hepatitis B immune; hepatitis C negative |
| Symptoms | Cough, one more streak of blood, night sweats |
| Decision | Four-month rifapentine-moxifloxacin regimen, first dose today |
| Isolation | At home; lessons online |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Cough with morning sputum; one more streak of blood since the first visit; no breathlessness at rest |
| Constitutional | Positive | Night sweats and evening fevers; poor appetite |
| Musculoskeletal | Negative | No tendon or joint pain |
| Neurological | Negative | No numbness or tingling; fine finger movements normal |
| Psychiatric | Positive | Anxious and low, but relieved to know the diagnosis; no thoughts of suicide or self-harm |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Rifapentine 150 mg tablets, eight tablets (1200 mg) daily with food | 1200 mg once daily with a meal by video-observed therapy with the health department, seven days a week, for 17 weeks (119 doses) | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Moxifloxacin 400 mg tablet, one tablet daily | 400 mg once daily with the other drugs by video-observed therapy with the health department, seven days a week, for 17 weeks; no mineral supplements within 4 hours before or 8 hours after | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Isoniazid 300 mg tablet, one tablet daily | 300 mg once daily by video-observed therapy with the health department, seven days a week, for 17 weeks | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Pyrazinamide 500 mg tablets, two tablets (1000 mg) daily | 1000 mg once daily by video-observed therapy with the health department, seven days a week, for the eight-week intensive phase (weight band 40 to under 55 kg) | Oral route | 2026-03-20 to 2026-05-14 | completed | S |
| Vitamin B6 (pyridoxine) 50 mg tablet, one tablet daily | 50 mg once daily with isoniazid | Oral route | 2026-03-20 to 2026-07-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-20 | Body height | 170 | cm | S |
| 2026-03-20 | Body weight | 48.4 | kg | S |
| 2026-03-20 | Body mass index (BMI) [Ratio] | 16.7 | kg/m2 | S |
| 2026-03-20 | Systolic blood pressure | 102 | mm[Hg] | S |
| 2026-03-20 | Diastolic blood pressure | 64 | mm[Hg] | S |
| 2026-03-20 | Heart rate | 98 | /min | S |
| 2026-03-20 | Respiratory rate | 18 | /min | S |
| 2026-03-20 | Body temperature | 37.6 | Cel | S |
| 2026-03-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
Vital signs recorded on 2026-03-20; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin and tired; weight 48.4 kg; temperature 37.6 °C, pulse 98; seen in an airborne infection isolation room with a respirator |
| Respiratory | Coarse crackles and bronchial breathing over the right upper zone; fine crackles at the left apex |
| Abdomen | Soft; liver not enlarged |
| Musculoskeletal | Achilles and wrist tendons non-tender, as a baseline before moxifloxacin |
| Neurological | Normal light touch and vibration in the fingers and feet, as a baseline before isoniazid |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Cough for about three months, blood-streaked sputum for two weeks, night sweats, and weight loss of about 6 kg in a man of 28, with a right upper lobe cavity on chest X-ray and CT: suspected pulmonary tuberculosis; home airborne isolation and three sputum samples for acid-fast smear, nucleic acid amplification, and culture | resolved | confirmed | R04.2 | S — Synthetic presenting problem linked to his documented chronic cough and hemoptysis; superseded by the diagnosis at the second visit. |
| Pulmonary tuberculosis of the right upper lobe, cavitary and sputum smear-positive, confirmed by nucleic acid amplification without rifampin resistance | active | confirmed | A15.0 | S — Synthetic modern coding of his documented tuberculosis, chosen over the disputed genetic and cardiac alternatives; the cavity and all bacteriology are synthetic. |
| Moderate protein-calorie malnutrition: BMI 16.8, about 11 percent weight loss in three months, and albumin 3.2 g/dL | active | confirmed | E44.0 | S — Synthetic nutrition diagnosis anchored to his documented frailty and exhaustion. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Symptom review: cough, sputum, hemoptysis, fever, night sweats | Every visit | Completed today | Cough, one more streak of blood, night sweats; no improvement yet before treatment |
| Examination | Weight, with the pyrazinamide dose checked against the weight band | Monthly | Completed today | 48.4 kg: pyrazinamide 1000 mg for the 40 to under 55 kg band |
| Medication safety | Adverse effects: hepatitis symptoms, tendon pain, numbness or tingling, rash, nausea, orange body fluids | Every visit | Completed today | Baseline tendon and nerve examination normal; warning symptoms explained |
| Laboratory | Liver tests (ALT, AST, bilirubin) | Baseline; repeat for symptoms or risk factors (here at two to three weeks, for low weight and albumin) | Up to date | Baseline ALT 18, AST 24, bilirubin 0.5, all normal; repeat ordered for the next visit |
| Laboratory | Potassium, calcium, magnesium, platelets, creatinine | Baseline, then as indicated | Up to date | Baseline potassium 4.0, calcium 9.0, magnesium 2.0, platelets 442 (raised with inflammation), creatinine 0.78 |
| Medication safety | Electrocardiogram (QT interval) | Not routine; only if clinically indicated | Not indicated | No QT history, no QT-prolonging medicines, normal potassium and magnesium |
| Laboratory | Sputum acid-fast smear and culture | Baseline, then monthly until two consecutive cultures are negative | Completed today | Three baseline smears 2+, 2+, 1+; cultures pending |
| Laboratory | Nucleic acid amplification test with rifampin resistance | At baseline | Completed today | Mycobacterium tuberculosis complex detected; rifampin resistance not detected |
| Laboratory | Rapid molecular testing for isoniazid and fluoroquinolone resistance | At baseline | Ordered | Sent on the first sample; pending |
| Laboratory | Phenotypic susceptibility (rifampin, isoniazid, pyrazinamide, moxifloxacin) | At baseline | Ordered | On the culture isolate when it grows |
| Laboratory | Interferon-gamma release assay | At baseline | Completed today | Positive; supports, but could not by itself prove or exclude, active tuberculosis |
| Laboratory | HIV test | At baseline | Completed today | HIV-1/2 antigen and antibody negative |
| Laboratory | Hepatitis B and C serology | At baseline | Completed today | Hepatitis B surface antigen and core antibody negative, surface antibody positive (vaccinated); hepatitis C antibody negative |
| Imaging | Chest X-ray | Baseline; at two months only if baseline cultures were negative; end of treatment optional | Up to date | Right upper lobe cavity on X-ray and CT at the first visit |
| Medication safety | Doses observed and the completion clock (56 doses within 70 days, 63 within 84 days, 119 within five months) | Every visit | Completed today | Video-observed therapy set up with the health department; first dose observed in clinic today |
| Medication safety | Drug interactions: rifapentine, and mineral products with moxifloxacin | With every new medicine or supplement | Completed today | No other medicines; mineral products to be kept apart from moxifloxacin; orange urine and tears expected |
| Self-management | Home airborne isolation and the release criteria | Until three negative smears, clinical improvement, and two weeks of treatment | Completed today | Continues at home; lessons online |
| Referral | Report to the health department | Same day as suspicion and on confirmation | Completed today | Suspected case reported at the first visit; confirmation sent today |
| Referral | Contact investigation (students, friends, close contacts) | Led by the health department from diagnosis | Referred | Health department listing his students and other close contacts; their results are not part of his record |
| Survey | Depression screen (PHQ-9) | At diagnosis, at two months, and at the end of treatment | Up to date | 7 at the first visit, item 9 scored 0 |
| Self-management | Nutrition: dietitian, intake, supplement drinks | Every visit until weight is restored | Ordered | First dietitian visit by video this week |
| Laboratory | Sweat chloride and serum alpha-1 antitrypsin | Once, to address the alternatives | Ordered | Advised by infectious diseases; at the next visit, once he is out of isolation |
| Referral | Infectious diseases review | At diagnosis, at two months, and at the end of treatment | Completed today | Seen today by Dr. Kowalczyk-Grant |
Goal progress:
Guideline basis: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis (2016); Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022 (2022); An official ATS statement: hepatotoxicity of antituberculosis therapy (2006); Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC (2005); Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation (2017); American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency (2003); Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: characteristics recommended for the identification and documentation of adult malnutrition (undernutrition) (2012); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Release smears in the third week, then review at about two and a half weeks with liver tests, the sweat chloride test, and the alpha-1 antitrypsin level. Call the same day for hepatitis symptoms or tendon pain. Next scheduled visit 2026-04-07: two-and-a-half-week review: release from isolation, return to teaching, liver tests, and tests for cystic fibrosis and alpha-1 antitrypsin deficiency. [S]